Total pharma industry venture financing deals in May 2019 worth $1.21bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 13.9% over the previous month and a drop of 28.4% when compared with the last 12-month average, which stood at $1.69bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $795.66m. At the country level, the US topped the list in terms of deal value at $795.66m.
In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of venture financing deals activity in May 2019 was the US with 45 deals, followed by China with five and the UK with four.
In 2019, as of the end of May 2019, pharma venture financing deals worth $7.58bn were announced globally, marking a decrease of 26.6% year on year.
Pharma industry venture financing deals in May 2019: Top deals
The top five pharma industry venture financing deals accounted for 42.8% of the overall value during May 2019.
The combined value of the top five pharma industry venture financing deals stood at $516.83m, against the overall value of $1.21bn recorded for the month. The top announced pharma industry venture financing deal tracked by GlobalData in May 2019 was Deyi Capital, Gaoke Xinyi Capital, Gongqingcheng Hanren, Huaxin Century Investment Group, Loyal Valley Capital, Nanjing Gaoke Xinchuang Investment, Qianlong Capital, SDIC Unity Capital, Shiyu Capital Group and Yuansheng Venture Capital’s $170.83m venture financing of Allist Shanghai Pharmaceutical Technology.
In second place was the $120m venture financing of AlloVir by EcoR1 Capital, F2 Ventures, Fidelity Management & Research, Gilead Sciences, SVB Leerink, Redmile Group, Samsara BioCapital and Invus Group and in third place was Abingworth, BVF Partners, Frazier Healthcare Partners, Greenspring Associates, Janus Henderson Investors, Medicxi Ventures (UK), RA Capital Management, Richard King Mellon Foundation and Sahsen Ventures’ $90m venture financing of Phathom Pharmaceuticals.
The $76m venture financing of Concentric Analgesics by Cowen Healthcare Investments, Kern Whelan Capital, Oracle Investment Management and Venrock Healthcare Capital Partners and Adrian Cheng, Advantech Capital, China Venture Capital Fund Corporation, Hudson Bay Capital Management and PAG (formerly Pacific Alliance Group)’s venture financing of Jiangsu Alphamab Biopharmaceuticals for $60m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
